Last reviewed · How we verify
Ketamine 0.5mg/kg
Ketamine, at a dose of 0.5mg/kg, is an anesthetic and analgesic agent primarily used for inducing and maintaining anesthesia. It is known for its rapid onset and short duration of action, making it suitable for various medical procedures. Developed by The University of Hong Kong, this formulation does not have an FDA label, indicating it may be used in research or clinical trials. Ketamine's unique mechanism of action involves NMDA receptor antagonism, which can also produce dissociative and hallucinogenic effects. Despite its potential for misuse, ketamine has shown promise in treating conditions such as depression and chronic pain.
At a glance
| Generic name | Ketamine 0.5mg/kg |
|---|---|
| Also known as | Group K1 |
| Sponsor | The University of Hong Kong |
| Drug class | Dissociative anesthetic |
| Target | NMDA receptors |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
Pipeline indications
Common side effects
Drug interactions
- Benzodiazepines
- Opioids
Key clinical trials
- Pain Reduction for Limb Injuries in Pediatric Emergency Departments: Intranasal Fentanyl or Intranasal Ketamine vs Oral Morphine (PHASE3)
- Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP) (EARLY_PHASE1)
- Ketamine + Cognitive Training for Suicidality in the Medical Setting (PHASE4)
- Optimal Timing of Ketamine Initiation for SCD Pain (PHASE3)
- Ketamine for Treatment-Resistant Bipolar Disorder (PHASE2)
- Pilot Study of RR-HNK in OCD (PHASE1, PHASE2)
- Repeated Neurocognitive Measurements in Depressed Patients (PHASE1, PHASE2)
- Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |